UTv Videos

"I think one of the key things is when we look at things like sensitivity and specificity, sensitivity is very much reliant on the incidence of a disease or the state of the disease," says Brian F. Chapin, MD.

Karim Fizazi, MD, PhD, highlights the TALAPRO-2 trial, which led to the FDA approval of talazoparib plus enzalutamide for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.

"There are a lot of exciting data that are coming out, and, of course, a lot of physicians and physician-scientists [who] are interested in these questions, and we’re working on that," says Sophia C. Kamran, MD.

“Looking at the impressive results for cohort K, with enfortumab, it's amazing what that is going to provide our patients,” says Joshua J. Meeks, MD, PhD.

"Integration of APPs can be useful to address some of the issues we have nowadays such as access and shortages," says Omer Raheem, MD, MSc, MCh Urol, MCRSI.

"If there’s recurrence of muscle-invasive bladder cancer within the bladder, you can perform salvage cystectomy at that point…. It is a bit more complex, so it’s great to have a high-volume surgeon who has performed these before," says Sophia C. Kamran, MD.

“We found some BRCA1 and BRCA2 mutations, as well as CDK12 mutations, in our cohort of patients with intraductal carcinoma of the prostate. Those are things that you could use now for clinical decision-making with PARP inhibitors with their approved indications,” says Benjamin Miron, MD.

“The field of advanced RCC is evolving very quickly to a precision medicine approach where we're trying to individualize therapies,” says Thomas E. Hutson, DO, PharmD, FACP.

“These are high-risk patients and they do have a high likelihood of having advanced or metastatic disease in the future,” says Benjamin Miron, MD.

“The goal at the end of the day is to get exposure of your patient [with renal cell carcinoma] to as many of the most active agents as possible,” says Thomas E. Hutson, DO, PharmD, FACP.

“Those pipeline programs that actually foster a sense of community and family, those are the pipeline programs that really do well,” says Randy Vince, MD, MS.

“We know that with that low toxicity and good functional outcomes, it's an excellent treatment to offer patients,” says Sophia C. Kamran, MD.

"For one thing, we're really interested in looking at plant-based diets in patients who are at high genetic risk for prostate cancer," says Stacy Loeb, MD, MSc.

“It's very helpful when we're looking at how we counsel patients about the stage of their disease,” says Brian F. Chapin, MD.

“Surprisingly, testosterone was not independently associated with frailty on our analysis, but on multivariable analysis, both hospital frailty risk score and low preoperative T were independently associated with 180-day readmission,” says Jasmine Lin, MD.

"Nonmetastatic castration-resistant prostate cancer remains an incurable disease state," says Alicia Morgans, MD.

“I would say that overall, the oncologic outcomes are equivalent between the [bladder-sparing treatment and radical cystectomy] for well-selected patients,” says Sophia C. Kamran, MD.

"We found that consuming more plant-based food was associated with significantly better scores for the urinary domains of the quality of life questionnaire," says Stacy Loeb, MD, MSc.

“We're still very interested in early-stage bladder cancer, those at high risk do not respond to BCG,” says Joshua J. Meeks, MD, PhD.

“There's not a perfect chemotherapy; there are a lot of different options, and then other factors to consider would be the field and the dose,” says Sophia Kamran, MD.

"There continues to be immense interest in urinary markers for bladder cancer," says Badrinath Konety, MD, MBA.

“I think the importance of this is that these are more accurate than our current imaging studies in helping us to better counsel patients on the expected treatment options given their current situation,” says Brian F. Chapin, MD.

“I would say that patients who have a very poor bladder function to start with would be a better candidate for radical cystectomy,” says Sophia C. Kamran, MD.

“There are a lot of different ways that we can potentially use these complementary and alternative therapies to help mitigate symptoms in our patients across the realm of urology,” said Sarah P. Psutka, MD.

“Obviously it's important to have options when we're looking at the various tracers that we're using for evaluation of patients with prostate cancer,” says Brian F. Chapin, MD.

"We found in both unadjusted and adjusted analyses that patients seemed to discontinue enzalutamide and apalutamide at slightly earlier time points than darolutamide," said Alicia Morgans, MD.

Rohan Garje, MD, highlights the need for molecular profiling of sarcomatoid urothelial carcinoma tumors as a gateway to advancing the treatment paradigm for this rare bladder cancer variant.

“It’s very important to really talk to the patients and understand any toxicities because the side effects are well managed if they’re caught early,” says Shilpa Gupta, MD.

“It's hard for us as physicians to think about anything other than continuing to put the accelerator into the red zone. But sometimes, a little bit of self-awareness can allow you to sustain a career for many years longer,” says Colin P. West, MD, PhD.

"It pretty much has been adopted around the world so that about 80% of men who are diagnosed with low-risk prostate cancer go on active surveillance. In Sweden, it's about 80%. That's considered the goal. But the United States has been slow in adopting this," says William J. Catalona, MD.